Skip to main content

Table 3 The effects of long-term treatment by LA therapy (average yearly reduction) on selected parameters of lipid metabolism, inflammatory biomarkers, and soluble endoglin

From: Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

Parameter HeFH (n = 10) HeFH (n = 10) HoFH (n = 4) HoFH (n = 4)
Lipids, mmol/L Decrease, n (%) Mean decrease (SD)/year Decrease, n (%) Mean decrease (SD)/year
TC 8 (80) 0.18 (0.08) 4 (100) 0.93 (1.2)
LDL-C 6 (60) 0.18 (0.06) 2 (50) 0.37 (0.19)
HDL-C 5 (50) 0.04 (0.01) 2 (50) 0.04 (0.01)
apoB 1 (10) 0.06 (0) 0 (0)
Soluble endoglin, ng/mL 3 (30) 0.37 (0.15) 1 (25) 0.52 (0)
CD40L, pg/mL 3 (30) 714 (193) 2 (50) 477 (122)
hsCRP, mg/L 0 (0) 3 (75) 0.62 (0.49)
MCP-1, pg/mL 3 (30) 27.29 (4.84) 1 (25) 15.99 (0)
sP-selectin, ng/mL 4 (40) 9.92 (6.43) 0 (0)
  1. Data shows how many patients LA resulted in the change of studied parameters. Moreover, we show an average yearly reduction of levels/biomarkers after LA (where the average is computed over those patients exhibiting a statistically significant reduction)